Sarepta Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SRPT Nasdaq 2830 www.sarepta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at Upcoming Investor Conferences - Oct 26th, 2026 2:30 pm
How Much Downside Is Left In Moderna Stock? - Oct 23rd, 2026 2:00 am
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results - Oct 22nd, 2026 6:30 am
What Is The Case For Waiting On Moderna Stock? - Oct 16th, 2026 8:44 am
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting - Oct 14th, 2026 6:30 am
Where Could Moderna's Next Growth Come From? - Oct 12th, 2026 3:01 pm
Global Capsid Tropism Screening Platforms Market Report 2026 | Capitalize on 14.4% CAGR to $1.45B by 2030 as Sarepta, Voyager, REGENXBIO and Dyno Scale AI and NGS Screening - Oct 12th, 2026 7:59 am
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics - Oct 7th, 2026 3:29 pm
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 30th, 2026 2:30 pm
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne - Sep 30th, 2026 6:30 am
Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn - Sep 26th, 2026 2:07 pm
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress - Sep 25th, 2026 6:30 am
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting - Sep 24th, 2026 6:30 am
Was Moderna Stock's Cancer Vaccine Run Visible In Advance? - Sep 22nd, 2026 11:39 am
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics - Sep 15th, 2026 3:58 am
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near - Sep 14th, 2026 11:02 pm
Novartis Stock Tanks Following Third Major Pipeline Setback - Sep 8th, 2026 2:26 pm
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - Sep 8th, 2026 9:04 am
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - Sep 8th, 2026 7:00 am